Douglas G Tilley

List of Publications by Year
in descending order

83 papers	3,589 citations	117625 34 h-index	138484 58 g-index
84 all docs	84 docs citations	84 times ranked	4452 citing authors

#	Article	IF	Citations
1	Î²-Arrestinâ€“mediated Î²1-adrenergic receptor transactivation of the EGFR confers cardioprotection. Journal of Clinical Investigation, 2007, 117, 2445-2458.	8.2	405
2	Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System. Molecular Pharmacology, 2003, 64, 533-546.	2.3	289
3	Î²-Blockers alprenolol and carvedilol stimulate Î²-arrestin-mediated EGFR transactivation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14555-14560.	7.1	241
4	Early Hyperlipidemia Promotes Endothelial Activation via a Caspase-1-Sirtuin 1 Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 804-816.	2.4	197
5	G Proteinâ€“Dependent and G Proteinâ€“Independent Signaling Pathways and Their Impact on Cardiac Function. Circulation Research, 2011, 109, 217-230.	4.5	126
6	Î²-arrestinâ€“biased signaling through the Î² ₂ -adrenergic receptor promotes cardiomyocyte contraction. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4107-16.	7.1	94
7	Î²-Arrestin Mediates Î²1-Adrenergic Receptor-Epidermal Growth Factor Receptor Interaction and Downstream Signaling. Journal of Biological Chemistry, 2009, 284, 20375-20386.	3.4	92
8	Role of Epidermal Growth Factor Receptor and Endoplasmic Reticulum Stress in Vascular Remodeling Induced by Angiotensin II. Hypertension, 2015, 65, 1349-1355.	2.7	82
9	BAG3: a new player in the heart failure paradigm. Heart Failure Reviews, 2015, 20, 423-434.	3.9	79
10	GRK5-Mediated Exacerbation of Pathological Cardiac Hypertrophy Involves Facilitation of Nuclear NFAT Activity. Circulation Research, 2014, 115, 976-985.	4.5	73
11	Expression of Phosphodiesterase 4D (PDE4D) Is Regulated by Both the Cyclic AMP-dependent Protein Kinase and Mitogen-activated Protein Kinase Signaling Pathways. Journal of Biological Chemistry, 2000, 275, 26615-26624.	3.4	72
12	Role of Î²-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Review of Cardiovascular Therapy, 2006, 4, 417-432.	1.5	70
13	Decreased Levels of BAG3 in a Family With a Rare Variant and in Idiopathic Dilated Cardiomyopathy. Journal of Cellular Physiology, 2014, 229, 1697-1702.	4.1	68
14	Nuclear Translocation of Cardiac G Protein-Coupled Receptor Kinase 5 Downstream of Select Gq-Activating Hypertrophic Ligands Is a Calmodulin-Dependent Process. PLoS ONE, 2013, 8, e57324.	2.5	60
15	Î²-Adrenergic Regulation of Cardiac Progenitor Cell Death Versus Survival and Proliferation. Circulation Research, 2013, 112, 476-486.	4.5	59
16	Interleukin-10 Inhibits Bone Marrow Fibroblast Progenitor Cellâ€“Mediated Cardiac Fibrosis in Pressure-Overloaded Myocardium. Circulation, 2017, 136, 940-953.	1.6	57
17	Association of Variants in <i>BAG3</i> With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiology, 2018, 3, 929.	6.1	57
18	BAG3 regulates contractility and Ca2+ homeostasis in adult mouse ventricular myocytes. Journal of Molecular and Cellular Cardiology, 2016, 92, 10-20.	1.9	56

#	Article	IF	Citations
19	Caspase-1 mediates hyperlipidemia-weakened progenitor cell vessel repair. Frontiers in Bioscience - Landmark, 2016, 21, 178-191.	3.0	54
20	Leukocyte-Expressed Î² ₂ -Adrenergic Receptors Are Essential for Survival After Acute Myocardial Injury. Circulation, 2016, 134, 153-167.	1.6	53
21	Vascular Smooth Muscle Cell Phosphodiesterase (PDE) 3 and PDE4 Activities and Levels are Regulated by Cyclic AMP in Vivo. Molecular Pharmacology, 2002, 62, 497-506.	2.3	51
22	Physiologic and cardiac roles of Î²-arrestins. Journal of Molecular and Cellular Cardiology, 2009, 46, 300-308.	1.9	50
23	Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury. Basic Research in Cardiology, 2017, 112, 62.	5.9	50
24	The Role of Leukocytes in Diabetic Cardiomyopathy. Frontiers in Physiology, 2018, 9, 1547.	2.8	50
25	The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray. Molecular Pharmacology, 2015, 88, 265-272.	2.3	48
26	Î²2-Adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15126-15131.	7.1	48
27	Beta-Arrestin-Mediated Signaling in the Heart. Circulation Journal, 2008, 72, 1725-1729.	1.6	46
28	Bcl-2â€"associated athanogene 3 protects the heart from ischemia/reperfusion injury. JCI Insight, 2016, 1, e90931.	5.0	40
29	Vascular Smooth Muscle Cell Phenotype-Dependent Phosphodiesterase 4D Short Form Expression: Role of Differential Histone Acetylation on cAMP-Regulated Function. Molecular Pharmacology, 2005, 68, 596-605.	2.3	39
30	Î²-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. Journal of Molecular and Cellular Cardiology, 2014, 72, 39-51.	1.9	38
31	Arginine vasopressin receptor signaling and functional outcomes in heart failure. Cellular Signalling, 2016, 28, 224-233.	3.6	37
32	Pepducin-mediated cardioprotection via Î²-arrestin-biased Î²2-adrenergic receptor-specific signaling. Theranostics, 2018, 8, 4664-4678.	10.0	37
33	Differential Activation of Cultured Neonatal Cardiomyocytes by Plasmalemmal Versus Intracellular G Protein-coupled Receptor 55. Journal of Biological Chemistry, 2013, 288, 22481-22492.	3.4	36
34	Orphan Nuclear Receptor Nur77 Inhibits Cardiac Hypertrophic Response to Beta-Adrenergic Stimulation. Molecular and Cellular Biology, 2015, 35, 3312-3323.	2.3	36
35	Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues. Molecular Pharmacology, 2002, 61, 1033-1040.	2.3	34
36	Î²-Adrenergic Receptorâ€"Mediated Cardiac Contractility Is Inhibited via Vasopressin Type 1A-Receptorâ€"Dependent Signaling. Circulation, 2014, 130, 1800-1811.	1.6	34

#	Article	IF	Citations
37	Cardiomyocyte-GSK-3Î± promotes mPTP opening and heart failure in mice with chronic pressure overload. Journal of Molecular and Cellular Cardiology, 2019, 130, 65-75.	1.9	34
38	Nesfatinâ€1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats. Journal of Neurochemistry, 2013, 126, 739-748.	3.9	33
39	Adeno-Associated Virus Serotype 9â€"Driven Expression of BAG3 Improves LeftÂVentricular Function in Murine Hearts With Left Ventricular Dysfunction Secondary to a Myocardial Infarction. JACC Basic To Translational Science, 2016, 1, 647-656.	4.1	32
40	Leukocyte-Dependent Regulation of Cardiac Fibrosis. Frontiers in Physiology, 2020, 11, 301.	2.8	32
41	Arginine Vasopressin Enhances Cell Survival via a G Proteinâ€"Coupled Receptor Kinase 2/<i>Î²</i>-Arrestin1/Extracellular-Regulated Kinase 1/2â€"Dependent Pathway in H9c2 Cells. Molecular Pharmacology, 2013, 84, 227-235.	2.3	30
42	Altered Phosphodiesterase 3-Mediated cAMP Hydrolysis Contributes to a Hypermotile Phenotype in Obese JCR:LA-cp Rat Aortic Vascular Smooth Muscle Cells: Implications for Diabetes-Associated Cardiovascular Disease. Diabetes, 2002, 51, 1194-1200.	0.6	29
43	G protein-coupled receptor kinase 5 (GRK5) contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure. Cardiovascular Research, 2022, 118, 169-183.	3.8	27
44	Î²2-adrenergic receptor-mediated mitochondrial biogenesis improves skeletal muscle recovery following spinal cord injury. Experimental Neurology, 2019, 322, 113064.	4.1	24
45	Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic Î²-adrenergic receptor stimulation. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H316-H330.	3.2	23
46	Cardiac GPCRâ€"Mediated EGFR Transactivation: Impact and Therapeutic Implications. Journal of Cardiovascular Pharmacology, 2017, 70, 3-9.	1.9	23
47	Designer Approaches for G Proteinâ€"Coupled Receptor Modulation for Cardiovascular Disease. JACC Basic To Translational Science, 2018, 3, 550-562.	4.1	23
48	G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart. Journal of Molecular and Cellular Cardiology, 2018, 123, 108-117.	1.9	22
49	Increased Vasopressin 1A Receptor Expression in Failing Human Hearts. Journal of the American College of Cardiology, 2014, 63, 375-376.	2.8	21
50	Cardiac Dysfunction in HIVâ€1 Transgenic Mouse: Role of Stress and BAG3. Clinical and Translational Science, 2015, 8, 305-310.	3.1	20
51	Prior beta blocker treatment decreases leukocyte responsiveness to injury. JCI Insight, 2019, 4, .	5.0	20
52	Direct evidence of intracrine angiotensin II signaling in neurons. American Journal of Physiology - Cell Physiology, 2014, 306, C736-C744.	4.6	19
53	Troglitazone stimulates Î²-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochemical and Biophysical Research Communications, 2010, 396, 921-926.	2.1	18
54	Impact of paroxetine on proximal Î²-adrenergic receptor signaling. Cellular Signalling, 2017, 38, 127-133.	3.6	18

#	Article	IF	Citations
55	Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165609.	3.8	18
56	Î²-Adrenergic Receptor-Dependent Alterations in Murine Cardiac Transcript Expression Are Differentially Regulated by Gefitinib In Vivo. PLoS ONE, 2014, 9, e99195.	2.5	17
57	Dynamic mass redistribution analysis of endogenous Î²â€adrenergic receptor signaling in neonatal rat cardiac fibroblasts. Pharmacology Research and Perspectives, 2014, 2, e00024.	2.4	17
58	Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2011, 11, 99-111.	1.2	16
59	Loss of Protease-Activated Receptor 4 Prevents Inflammation Resolution and Predisposes the Heart to Cardiac Rupture After Myocardial Infarction. Circulation, 2020, 142, 758-775.	1.6	14
60	Cardiac Progenitor Cells Engineered With Î²ARKct Have Enhanced Î²-Adrenergic Tolerance. Molecular Therapy, 2014, 22, 178-185.	8.2	12
61	Urotensin <scp>II</scp> promotes vagalâ€mediated bradycardia by activating cardiacâ€projecting parasympathetic neurons of nucleus ambiguus. Journal of Neurochemistry, 2014, 129, 628-636.	3.9	12
62	Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload. JACC Basic To Translational Science, 2020, 5, 69-83.	4.1	11
63	Skeletal Muscle-specific G Protein-coupled Receptor Kinase 2 Ablation Alters Isolated Skeletal Muscle Mechanics and Enhances Clenbuterol-stimulated Hypertrophy. Journal of Biological Chemistry, 2016, 291, 21913-21924.	3.4	9
64	ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation. Journal of Cell Communication and Signaling, 2020, 14, 111-126.	3.4	9
65	Muscarinic receptors promote pacemaker fate at the expense of secondary conduction system tissue in zebrafish. JCI Insight, 2019, 4, .	5.0	9
66	Epidermal growth factor receptor-dependent maintenance of cardiac contractility. Cardiovascular Research, 2022, 118, 1276-1288.	3.8	8
67	Loss of dynamic regulation of G protein-coupled receptor kinase 2 by nitric oxide leads to cardiovascular dysfunction with aging. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1162-H1175.	3.2	7
68	Vasopressin typeÂ1A receptor deletion enhances cardiac contractility, Î²-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. Clinical Science, 2016, 130, 2017-2027.	4.3	6
69	DUSPs as critical regulators of cardiac hypertrophy. Clinical Science, 2017, 131, 155-158.	4.3	4
70	Pepducin ICL1-9-Mediated Î²2-Adrenergic Receptor-Dependent Cardiomyocyte Contractility Occurs in a Gi Protein/ROCK/PKD-Sensitive Manner. Cardiovascular Drugs and Therapy, 2023, 37, 245-256.	2.6	4
71	Unexpected Cardiac Hypertrophy by Epidermal Growth Factor Receptor Silencing. Hypertension, 2013, 61, e46.	2.7	3
72	Epidermal growth factor receptor association with Î²1-adrenergic receptor is mediated via its juxtamembrane domain. Cellular Signalling, 2021, 78, 109846.	3.6	2

#	Article	IF	Citations
73	Recent advances in GPCR-regulated leukocyte responses during acute cardiac injury. Current Opinion in Physiology, 2021, 19, 55-61.	1.8	2
74	Self-made allostery: endogenous COMP antagonizes pathologic AT1AR signaling. Cell Research, 2021, 31, 730-731.	12.0	2
75	GÎ±q Signaling in the Regulation of Autophagy and Heart Failure. Journal of Cardiovascular Pharmacology, 2017, 69, 212-214.	1.9	0
76	Regulation of PDE Expression in Arteries. , 2006, , .		0
77	AT1 A Râ€Î²â€arrestin signaling confers PPARÎ³ agonistâ€mediated myocyte contractility. FASEB Journal, 2010, 24, 586.3.	0.5	0
78	Acute cardiac gene expression changes mediated through betaâ€ARâ€mediated transactivation of EGFR in vivo. FASEB Journal, 2013, 27, 652.18.	0.5	0
79	Subtype specific Î²â€adrenerigic receptorâ€mediated transactivation of epidermal growth factor receptor decreases apoptosis through differential activation of ERK1/2 and Akt. FASEB Journal, 2013, 27, 652.10.	0.5	0
80	Abstract 16796: Î²2-Adrenergic Receptor Expression on Hematopoietic Cells is Critical for Survival Following Myocardial Infarction. Circulation, 2014, 130, .	1.6	0
81	Abstract 19409: Î²2-Adrenergic Receptor Regulation of Innate Immune Responses Following Acute Myocardial Injury. Circulation, 2015, 132, .	1.6	0
82	Abstract 578: Î²-arrestin-Biased Î²2-Adrenergic Receptor Signaling Enhances Cardiomyocyte Contractility via ROCK-Dependent Signaling. Circulation Research, 2018, 123, .	4.5	0
83	GRK5â€mediated Exacerbation of Ischemic Heart Failure Involves Cardiac Immune and Inflammatory Responses. FASEB Journal, 2019, 33, 676.7.	0.5	0